Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1994-10-20
2000-03-21
Goldberg, Jerome D.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
A61K 3135
Patent
active
060403349
ABSTRACT:
Methods of treating various cancers, such as prostatic adenocarcinoma, with inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMG Co-A), such as lovastatin, are provided. Dosing ranges, schedules and toxicities are included.
REFERENCES:
patent: 5130333 (1992-07-01), Pan et al.
patent: 5595734 (1997-01-01), Mikulski et al.
Week 8143, Derwent Publications Ltd, London, GB; AN 81-78653D & JP-A-56115717 (Endo, Akira) Sep. 11, 1981 (D4) discloses the prevention of hypertrophy by oral administration of monacolin K or ML-236B or derivatives thereof in a dosage of 0.5-1000 mg/kg/day.
Kort, W.J., et al. Clin. Expl. Metastasis 7:517 (1989).
Kelloff, G.J., et al. Journal of Cellular Biochemistry, Supp. 16H:1 (1992).
Mikulski, S.M., et al. Br. J. Cancer 66:304 (1992).
Soma, M.R., et al. Cancer Research 52:4348 (1992).
Sumi, S., et al. Gastroenterology 103:982 (1992).
Maltese, W.A., et al. Neurology 33:1294 (1983).
Thibault, A., et al. Clinical Cancer Research 2:483 (1996).
Duggan and Vickers, "Physiological Disposition of HMG-CoA-Reductase Inhibitors," Drug Metabolism Reviews, vol. 22, No. 4 (1990), pp. 333-362.
Sebti, et al., "Lovastatin, a Cholesterol Biosynthesis Inhibitor, Inhibits the Growth of Human H-ras Oncogene Transformed Cells in Nude Mice," Cancer Communications, vol. 3, No. 5 (1991), pp. 141-147.
Maltese, et al., "Suppression of Murine Neuroblastoma Growth Methylglutaryl-Coenzyme A Reductase," Journal of Clinical Investigation, vol. 76 (Nov. 1985), pp. 1748-1754.
Keyomarsi, et al., "Synchronization of Tumor and Normal Cells from G.sub.1 to Multiple Cell Cycles by Lovastatin," Cancer Research, vol. 51 (Jul. 1, 1991), pp. 3602-3609.
Mantell, et al., "Extended Clinical Safety Profile of Lovastatin," The American Journal of Cardiology, vol. 66, (Sep. 18, 1990), pp. 11B-15B.
Jakobisiak, et al., "Cell cycle-specific effects of lovastatin," Proc. Natl. Acad. Sci. USA, vol. 88 (May 1991), pp. 3628-3632.
Sepp-Lorenzino, et al., "Cellular distribution of cholesterogenesis-linked, phospho-isoprenylated proteins in proliferating cells," F.E.B.S. Letters, vol. 245, Nos. 1-2 (Mar. 1989), pp. 110-166.
Maltese and Sheridan, "Isoprenylated Proteins in Cultured Cells: Subcellular Distribution and Changes Related to Altered Morphology and Growth Arrest Induced by Mevalonate Deprivation," Journal of Cellular Physiology, vol. 133 (1987), pp. 471-481.
MacDonald, et al., "Preclinical Evaluation of Lovastatin," The American Journal of Cardiology, vol. 62 (Nov. 11, 1988), pp. 16J-27J.
Larsson, et al., "Abolition of Mevinolin-induced Growth Inhibition in Human Fibroblasts following Transformation by Simian Virus 40," Cancer Research, vol. 49 (Oct. 15, 1989), pp. 5605-5610.
Larsson, "Role of Biosynthesis of Cholesterol and Isoprenoid Derivatives in Regulation of G.sub.1 Progression and Cell Proliferation of 3T6 Cells," Journal of Cellular Physiology, vol. 133 (1987), pp. 163-168.
Fairbanks, et al., "Effects of Mevinolin and Mevalonate on Cell Growth in Several Transformed Cell Lines," Journal of Cellular Physiology, vol. 127 (1986), pp. 216-222.
Dujovne, et al., "Expanded Clinical Evaluation of Lovastatin (EXCEL) Study Results: IV. Additional Perspectives on the Tolerability of Lovastatin," The American Journal of Medicine, vol. 91 (suppl. 1B) (Jul. 31, 1991) pp. 1B-25S--1B-30S.
DeClue, et al., "Inhibition of Cell Growth by Lovastatin Is Independent of ras Function," Cancer Research, vol. 51 (Jan. 15, 1991), pp. 712-717.
Bradford, et al., "Expanded Clinical Evaluation of Lovastatin (EXCEL) Study Results: III. Efficacy in Modifying Lipoproteins and Implications for Managing Patients with Moderate Hypercholesterolemia," The American Journal of Medicine, vol. 91 (suppl. 1B) (Jul. 31, 1991), pp. 1B-18S-1B-24S.
Bradford, et al., "Expanded Clinical Evaluation of Lovastatin (EXCEL) Study: Design and Patient Characteristics of a Double-Blind, Placebo-Controlled Study in Patients with Moderate Hypercholesterolemia," The American Journal of Cardiology, vol. 66 (Sep. 18, 1990), pp. 44B-55B.
Bradford, et al., "I. Efficacy in Modifying Plasma Lipoproteins and Adverse Event Profile in 8245 Patients With Moderate Hypercholesterolemia," Arch. Intern. Med., vol. 151 (Jan. 1991), pp. 43-49.
Bansal, et al., "Apoptosis: mode of cell death induced in T cell leukemia lines by dexamethasone and other agents," The F.A.S.E.B. Journal, vol. 5 (Feb. 1991), pp. 212.
Alberts, "Discovery, Biochemistry and Biology of Lovastatin," The American Journal of Cardiology, vol. 62 (1988), pp. 10J-15J.
Kang Won Ki
Myers Charles
Neckers Len
Trepel Jane
Whitesell Luke
Goldberg Jerome D.
The United States of America as represented by the Secretary of
LandOfFree
Use of inhibitors of 3-hydroxy-3-methylglutaryl coenzyme a reduc does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of inhibitors of 3-hydroxy-3-methylglutaryl coenzyme a reduc, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of inhibitors of 3-hydroxy-3-methylglutaryl coenzyme a reduc will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-730775